Market Place
Sourcing Support
ILiAD Biotechnologies To Participate In Investor Conferences
01 Oct 2024 //
BUSINESSWIRE
Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15
05 Aug 2024 //
BUSINESSWIRE
ILiAD Selects Emmes Group To Conduct Phase III Pertussis Vaccine Studies
24 Jun 2024 //
CONTRACT PHARMA
ILiAD`s pertussis shot joins Trojan horse of childhood vaccines
28 May 2024 //
FIERCE BIOTECH
ILiAD Bio: Positive Phase 2b School-Age Data For Pertussis Vaccine BPZE1
28 May 2024 //
BUSINESSWIRE
ILiAD Announces Presentation at the 2023 World Vaccine Congress in Barcelona
18 Oct 2023 //
BUSINESSWIRE
ILiAD says homer hit in whooping cough vaccine challenge trial
08 Sep 2023 //
FIERCE BIOTECH
ILiAD Reports Demonstration of Protection Against B. pertussis Colonization
05 Sep 2023 //
BUSINESSWIRE
ILiAD Biotechnologies Announces Presentation at the World Vaccine Congress
05 Apr 2023 //
BUSINESSWIRE
ILiAD Announces Publication of BPZE1 Adult Phase 2b Results in The Lancet
10 Mar 2023 //
BUSINESSWIRE
ILiAD Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine
06 Sep 2022 //
BUSINESSWIRE
ILiAD Biotech to Present Additional Positive Data for Next Gen Pertussis Vaccine
27 Jun 2022 //
BUSINESSWIRE
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine
26 Apr 2022 //
BUSINESSWIRE
FDA Grants ILiAD Biotechnologies FTD for Next Gen Pertussis Vaccine BPZE1
03 Jan 2022 //
BUSINESSWIRE
ILiAD Announces First School-Age Participants Enrolled in Phase 2b SUPER Trial
17 Dec 2021 //
BUSINESSWIRE
ILiAD Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1
29 Sep 2021 //
BUSINESSWIRE
ILiAD Biotechnologies Announces Upcoming Presentation at the European Society
21 Oct 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.